A nationwide cohort study of the incidence of inflammatory bowel disease in Sweden from 1990 to 2014.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
27
10
2021
received:
29
09
2021
accepted:
05
12
2021
pubmed:
16
12
2021
medline:
16
4
2022
entrez:
15
12
2021
Statut:
ppublish
Résumé
Epidemiological studies have shown inconsistent incidence rates (IRs) for inflammatory bowel disease (IBD). To assess the incidence and temporal trends of IBD in Sweden. Nationwide cohort study based on diagnostic codes for IBD and biopsy reports registered through the ESPRESSO cohort in 1990-2014. Age-specific and age-standardised IRs and cumulative incidence were calculated. Overall, we identified 65 908 cases of incident IBD: ulcerative colitis (UC, n = 38 261, 58%), Crohn's disease (CD, n = 18 577, 28%) and IBD-U (n = 9070, 14%). During 1990-2014, the overall IRs per 100 000 person-years were 29.0 (95% CI: 27.3-30.7) for IBD, 16.9 (15.9-17.9) for UC, and 8.1 (7.7-8.6) for CD. For IBD-U, the IR was 5.2 (4.9-5.6) in 2002-2014. The annual incidence of IBD, UC and CD increased by approximately 7% per year between 1990 and 2001 (P < 0.001) and then decreased by 1%-2% per year from 2002 onwards (P < 0.001). IRs for IBD, UC and IBD-U were higher in males while the IR for CD was higher in females. The lifetime risk of IBD was about 2.5% for both sexes. In Sweden, the incidence of IBD in all subtypes increased in 1990-2001 but has since declined. One in 40 individuals is expected to be diagnosed with IBD during their lifetime.
Sections du résumé
BACKGROUND
Epidemiological studies have shown inconsistent incidence rates (IRs) for inflammatory bowel disease (IBD).
AIM
To assess the incidence and temporal trends of IBD in Sweden.
METHODS
Nationwide cohort study based on diagnostic codes for IBD and biopsy reports registered through the ESPRESSO cohort in 1990-2014. Age-specific and age-standardised IRs and cumulative incidence were calculated.
RESULTS
Overall, we identified 65 908 cases of incident IBD: ulcerative colitis (UC, n = 38 261, 58%), Crohn's disease (CD, n = 18 577, 28%) and IBD-U (n = 9070, 14%). During 1990-2014, the overall IRs per 100 000 person-years were 29.0 (95% CI: 27.3-30.7) for IBD, 16.9 (15.9-17.9) for UC, and 8.1 (7.7-8.6) for CD. For IBD-U, the IR was 5.2 (4.9-5.6) in 2002-2014. The annual incidence of IBD, UC and CD increased by approximately 7% per year between 1990 and 2001 (P < 0.001) and then decreased by 1%-2% per year from 2002 onwards (P < 0.001). IRs for IBD, UC and IBD-U were higher in males while the IR for CD was higher in females. The lifetime risk of IBD was about 2.5% for both sexes.
CONCLUSIONS
In Sweden, the incidence of IBD in all subtypes increased in 1990-2001 but has since declined. One in 40 individuals is expected to be diagnosed with IBD during their lifetime.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
691-699Informations de copyright
© 2021 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Références
Thurgate LE, Lemberg DA, Day AS, Leach ST. An overview of inflammatory bowel disease unclassified in children. Inflamm Intest Dis. 2019;4:97-103.
Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012;380:1590-1605.
Shah SC, Khalili H, Gower-Rousseau C, et al. Sex-based differences in incidence of inflammatory bowel diseases-pooled analysis of population-based studies from western countries. Gastroenterology. 2018;155:1079-1089.
Olén O, Erichsen R, Sachs MC, et al. Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study. Lancet Gastroenterol Hepatol. 2020;5:475-484.
Olén O, Askling J, Sachs MC, et al. Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964-2014. Gut. 2020;69:453-461.
Everhov Å, Sachs MC, Ludvigsson JF, et al. Work loss in relation to pharmacological and surgical treatment for Crohn's disease: a population-based cohort study. Clin Epidemiol. 2020;12:273-285.
Khalili H, Everhov ÅH, Halfvarson J, et al. Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis: results from a nationwide study in Sweden. Aliment Pharmacol Ther. 2020;52:655-668.
Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390:2769-2778.
Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54.
Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18:56-66.
Lophaven SN, Lynge E, Burisch J. The incidence of inflammatory bowel disease in Denmark 1980-2013: a nationwide cohort study. Aliment Pharmacol Ther. 2017;45:961-972.
Jussila A, Virta LJ, Kautiainen H, Rekiaro M, Nieminen U, Farkkila MA. Increasing incidence of inflammatory bowel diseases between 2000 and 2007: a nationwide register study in Finland. Inflamm Bowel Dis. 2012;18:555-561.
Lirhus SS, Hoivik ML, Moum B, Anisdahl K, Melberg HO. Incidence and prevalence of inflammatory bowel disease in Norway and the impact of different case definitions: a nationwide registry study. Clin Epidemiol. 2021;13:287-294.
Everhov AH, Halfvarson J, Myrelid P, et al. Incidence and treatment of patients diagnosed with inflammatory bowel diseases at 60 years or older in Sweden. Gastroenterology. 2018;154:518-528.
Kaplan GG, Bernstein CN, Coward S, et al. The impact of inflammatory bowel disease in Canada 2018: epidemiology. J Can Assoc Gastroenterol. 2019;2:S6-S16.
Stulman MY, Asayag N, Focht G, et al. Epidemiology of inflammatory bowel diseases in Israel: a nationwide Epi-Israeli IBD research nucleus study. Inflamm Bowel Dis. 2021;7:1784-1794.
Lapidus A. Crohn's disease in Stockholm County during 1990-2001: an epidemiological update. World J Gastroenterol. 2006;12:75-81.
Lapidus A, Bernell O, Hellers G, Persson PG, Lofberg R. Incidence of Crohn's disease in Stockholm County 1955-1989. Gut. 1997;41:480-486.
Ronnblom A, Samuelsson SM, Ekbom A. Ulcerative colitis in the county of Uppsala 1945-2007: incidence and clinical characteristics. J Crohns Colitis. 2010;4:532-536.
Sjöberg D, Holmström T, Larsson M, et al. Incidence and clinical course of Crohn's disease during the first year - results from the IBD Cohort of the Uppsala Region (ICURE) of Sweden 2005-2009. J Crohns Colitis. 2014;8:215-222.
Sjöberg D, Holmström T, Larsson M, et al. Incidence and natural history of ulcerative colitis in the Uppsala Region of Sweden 2005-2009 - results from the IBD cohort of the Uppsala Region (ICURE). J Crohns Colitis. 2013;7:351-357.
Eriksson C, Cao Y, Rundquist S, et al. Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Orebro, Sweden, 1963-2010. Aliment Pharmacol Ther. 2017;46:748-757.
Zhulina Y, Udumyan R, Henriksson I, Tysk C, Montgomery S, Halfvarson J. Temporal trends in non- stricturing and non-penetrating behaviour at diagnosis of Crohn's disease in Örebro, Sweden: a population-based retrospective study. J Crohns Colitis. 2014;8:1653.
Olén O, Erichsen R, Sachs MC, et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet. 2020;395:123-131.
Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.
Ludvigsson JF, Almqvist C, Bonamy A-K, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol. 2016;31:125-136.
Ludvigsson JF, Lashkariani M. Cohort profile: ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden). Clin Epidemiol. 2019;11:101-114.
Nguyen LH, Örtqvist AK, Cao Y, et al. Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden. Lancet Gastroenterol. 2020;5:986-995.
Elandt-Johnson RC, Johnson NL. Survival models and data analysis. Wiley; 1980.
Everhov ÅH, Sachs MC, Malmborg P, et al. Changes in inflammatory bowel disease subtype during follow-up and over time in 44,302 patients. Scand J Gastroenterol. 2019;54:55-63.
Burisch J, Pedersen N, Čuković-Čavka S, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut. 2014;63:588-597.
Segerman F, Clarkson S, Sjoberg K. Marked regional variations in the prevalence of inflammatory bowel disease in a limited geographical region are not associated with compounds in the drinking water. Scand J Gastroenterol. 2019;54:1250-1260.
Khalili H. Risk of inflammatory bowel disease with oral contraceptives and menopausal hormone therapy: current evidence and future directions. Drug Saf. 2016;39:193-197.
Cornish JA, Tan E, Similis C, Clark SK, Teare JP, Tekkis PP. The risk of oral contraceptives in the aetiology of inflammatory Bowel disease: a meta-analysis. Gut 2008;57:A113-A.
Everhov AH, Sachs MC, Ludvigsson JF, et al. Work loss in relation to pharmacological and surgical treatment for Crohn's disease: a population-based cohort study. Clin Epidemiol. 2020;12:273-285.
Coward S, Clement F, Benchimol EI, et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology. 2019;156:1345-1353.